VIDEO: BeST: Does a treat-to-target approach reduce RA mortality?

BOSTON - With follow up every 3 months, the survival rates of RA patients were comparable to those of the general population in a 10-year study of patients in the Netherlands. Dr. Iris Markusse of Leiden University Medical Center credits regimens that were tailored to keep the Disease Activity Score at levels of 2.4 or lower. Further, the medications used in this strategy did not increase patient mortality. Dr. Markusse discusses the findings of BeST in an exclusive interview at the annual meeting of the American College of Rheumatology.

BOSTON - With follow up every 3 months, the survival rates of RA patients were comparable to those of the general population in a 10-year study of patients in the Netherlands. Dr. Iris Markusse of Leiden University Medical Center credits regimens that were tailored to keep the Disease Activity Score at levels of 2.4 or lower. Further, the medications used in this strategy did not increase patient mortality. Dr. Markusse discusses the findings of BeST in an exclusive interview at the annual meeting of the American College of Rheumatology.

BOSTON - With follow up every 3 months, the survival rates of RA patients were comparable to those of the general population in a 10-year study of patients in the Netherlands. Dr. Iris Markusse of Leiden University Medical Center credits regimens that were tailored to keep the Disease Activity Score at levels of 2.4 or lower. Further, the medications used in this strategy did not increase patient mortality. Dr. Markusse discusses the findings of BeST in an exclusive interview at the annual meeting of the American College of Rheumatology.